Posted by Michael Wonder on 31 Oct 2016
Alprolix approved in Switzerland for the treatment of haemophilia B
28 October 2016 - Alprolix approved in Switzerland for the treatment of haemophilia B
Swedish Orphan Biovitrum today announces that the Swiss Agency for Therapeutic Products, Swissmedic, has approved Alprolix (eftrenonacog alfa) for the treatment of haemophilia B.
Alprolix is the only recombinant factor IX Fc fusion protein therapy approved in Switzerland for the treatment of haemophilia B.
